Navigation Links
TransGenRx Protein Therapeutics Technology to Support Research Related to Protein-Based HDL Therapies at Esperion Therapeutics
Date:6/21/2010

PLYMOUTH, Mich. and BATON ROUGE, La., June 21 /PRNewswire/ -- Esperion Therapeutics, a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that TransGenRx, a global leader in transgenic technology, will produce protein-based therapeutics to be used in the company's research efforts targeting HDL therapies for the treatment of cardio-metabolic disease. Under the terms of the agreement, TransGenRx will coordinate production of protein-based therapies for a range of research needs using a proprietary expression system.

Researchers at Esperion are working to develop novel therapies to treat cardio-metabolic disease including therapies based on HDL, the body's "good" cholesterol, which has been shown to play an important role in lipid management. The company's development platform includes therapies designed to mimic or enhance the function of HDL in managing and removing cholesterol and other lipids from atherosclerotic plaques. Researchers at Esperion have initiated preclinical and clinical research related to a variety of pathways for better lipid regulation to treat the full spectrum of cardio-metabolic diseases, from early risk factors to acute coronary syndromes and atherosclerosis.

"While HDL continues to show great promise in the treatment of cardiovascular disease, there have been significant challenges in the development of protein-based drug therapies. By working with the outstanding research and technology team at TransGenRx, we are positioned to access one of the most advanced, cost-effective protein expression technologies in the world to supply the protein-based therapies we will use in our research," said Roger Newton, Ph.D., President and CEO of Esperion. "This collaboration represents a tremendous advantage in our efforts to identify and access complex protein-based therapies that will lead to new treatments for cardio-metabolic disease in the years ahead."

On June 14, 2010, Esperion announced the establishment of a collaborative research agreement with the Cleveland Clinic Foundation, one of the world's leading academic medical centers. In this collaboration teams at Esperion and Cleveland Clinic are working to advance research involving HDL mimetics and other protein-based therapies to treat cardiovascular disease.

"In terms of both cost and complexity, the development of protein-based therapies requires broad expertise and targeted, advanced technology to be successful. At TransGenRx, our proprietary protein expression technology is uniquely suited to meet the key challenges in the production of therapeutic proteins, and we look forward to supporting the important work by the teams at Esperion and Cleveland Clinic in efforts to develop promising new HDL therapies," said Richard Cooper, Ph.D., Executive Vice President and Chief Scientific Officer of TransGenRx.

About TransGenRx

TransGenRx, a bio-pharmaceutical manufacturing company, has developed technology that significantly reduces the cost of producing protein-based drugs by using a high expressing avian cell line combined with a patented vector system. Patented and patent-pending processes allow TransGenRx to develop custom proteins to meet a wide range of specifications. The company's core technology involves the targeted integration of a desired gene sequence into virtually any animal or cell culture system and the controlled expression of that sequence to achieve a desired outcome (protein production, gene therapy, etc.) The Louisiana State University Agricultural Center has had an established research relationship with TransGenRx since 2002. For information visit www.tgrxinc.com.

About Esperion Therapeutics

Esperion Therapeutics, Inc., located in Plymouth, Michigan, discovers and develops novel therapies for the treatment of cardiovascular and metabolic diseases. The company is funded by top tier venture capital investors, including Aisling Capital, Alta Partners, Arboretum Ventures, Asset Management Company and Domain Associates. For more information please visit www.esperion.com.


'/>"/>
SOURCE Esperion Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Althea Technologies Acquires Altus Pharmaceuticals(R) Assets and IP Portfolio, Establishing Technology Platform for Protein Formulations.
2. California Natural Products Unveils CalNaturale(TM) Svelte(TM) All-Natural Sustained Energy Protein Drink
3. Bone Biologics Announces Another Major US Patent Issuance for Recombinant Protein Process
4. Repligen Receives Notice of Allowance for Recombinant Protein A Patent
5. Repligen Announces Long Term Supply Agreement with GE Healthcare for Recombinant Protein A
6. ForteBio Launches New Dip and Read(TM) Residual Protein A Detection Kit; Introduces Sidekick(TM) Offline Biosensor Immobilization Station for All Octet(R) Instruments
7. Fate Therapeutics iPSC Technology Awarded Top Industry Honors for Small Molecule and Protein Reprogramming Breakthroughs
8. Pfenex Grants Exclusive License to Merck & Co., Inc. for the Production of Proteins for Undisclosed Vaccine Program
9. Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds
10. Octapharma Group and Fresenius Kabi Enter Into an Exclusive License, Development and Supply Agreement for a HESylated Recombinant Protein
11. ZyStor Therapeutics, Inc. Cleared to Begin Clinical Trial for Targeted Protein Therapeutic for the Treatment of Pompe Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)...  PipelineRx, a leading medication management technology company ... of its SaaS-based telepharmacy platform, PowerGridRx™ , ... Midyear Clinical Meeting and Exhibition, December 5-7 in ... 300 hospital clients nationally, the Company is a ... dramatically improve pharmacy operations, enhance patient safety, and ...
(Date:12/2/2016)... 2016  Maxor National Pharmacy Services, LLC ("Maxor"), today announced ... ("PSI").  The combination of Texas -based Maxor ... PSI bring together both company,s clinical expertise and high-touch patient ... industry-leading specialty pharmacy. About Maxor ... , , ...
(Date:12/2/2016)... 2, 2016 Lianluo Smart Limited (Nasdaq: ... Company") which develops, markets and sells medical devices ... China and international markets, recently attended ... Treatment New Progress Forum, co-hosted by the Institute ... , Guangdong Provincial People,s Hospital and Cardiology ...
Breaking Medicine Technology:
(Date:12/2/2016)... Raleigh, NC (PRWEB) , ... December 02, 2016 , ... ... the Open Enrollment Period (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare ... plan (Part C) or prescription drug plan (Part D) need to make changes during ...
(Date:12/2/2016)... New York, NY (PRWEB) , ... December 02, ... ... today, featuring an inspirational interview of two ostomy patients, standing as living proof ... million people suffer from digestive diseases and issues that spike around the holidays. ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet ... in USA Today, which covers the innovative treatments, therapeutic technologies, and revolutionized nutrition ... lives. “We are prolonging life 6 years in the last 3 decades,” says ...
(Date:12/2/2016)... ... 02, 2016 , ... Universal Medical Systems, Inc. (UMS) the ... company to offer robotic imaging to veterinary medicine is sponsoring the appearance of ... the American Association of Equine Practitioners 62nd Annual Convention from December 4-6, 2016 ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Yisrayl Hawkins, at ... into how this current generation fits into Bible Prophecy. Yisrayl says this generation, known ... pointing to this conclusion, showing how the details line up exactly with Bible Prophecy ...
Breaking Medicine News(10 mins):